Clinical Trials AI Security Review for Healthcare
A clinical-trials AI security review should follow one proposed workflow from its source system through AI processing, human review, the downstream trial record, and archive. The useful output is a set of evidence requests tied to that system, its users, and its records. A security certificate or a general AI policy cannot show whether access, changes, corrections, and recovery work in the configuration a study will actually use.
This guide is for healthcare technology research and procurement planning. It is not medical, clinical, legal, privacy, security, regulatory, or compliance advice and does not certify a product or approve a study. A sponsor, investigator, site, quality lead, privacy and security team, and qualified legal or regulatory reviewers must determine which obligations apply. Record unanswered questions as open — owner/evidence required. Do not turn an absent document into a pass.
Follow one hypothetical trial workflow
Use eligibility prescreening as a hypothetical field example, not an observed test or a description of any real study. Replace every placeholder with a protocol-bound answer before asking a vendor to demonstrate controls:
- Trigger and source system: [protocol/version, site, authorized source system, data owner, extraction event, minimum fields, and excluded populations — open].
- AI processing: [exact function, configured software/model version, processing location, input and output classes, temporary copies, support access, and subprocessor — open].
- Human review: [qualified reviewer, source evidence visible to that reviewer, disagreement path, correction authority, and person who can pause processing — open].
- Downstream trial record: [whether the output remains a disposable suggestion or becomes a source, essential, or submitted record; receiving system, authoritative copy, transfer and reconciliation method — open].
- Archive and recovery: [retention owner, retrievable record and metadata, backup scope, restore test, and deletion or archival rule — open].
- Evidence pointer: [document ID, controlled sample or test ID, system/version, date, responsible owner, limitation, and recheck trigger — open].
The bracketed fields are prompts, not evidence that a control exists. One prescreening suggestion can involve an EHR extract, temporary AI input, reviewer decision, and a separate trial record; the actual boundary may differ. Do not infer that all of these copies are regulated records, ePHI, or accessible to the same parties. The case remains open — owner/evidence required until the team maps its real systems and purpose.
Six security and record-integrity gates
These six gates are an editorial review aid, not an official checklist, legal rule, validated instrument, or vendor score. For each gate, link the proposed use to evidence from the same configuration and record pass, fail, conditional, or open separately. A missing owner, failed integrity control, or failed recovery cannot be offset by price or expected time savings.
Gate 1: map systems, data, and trial records
Evidence to request: a versioned workflow/data/record map naming the sponsor, investigator, site, vendor, and any other actor; the source system, input fields, AI output, reviewer decision, downstream action, authoritative copy, transfer, retention, and archive. Ask the relevant owner to classify each record and document why ePHI, trial source or essential records, and FDA-submitted records do or do not enter scope. Ask where copies or metadata persist after an exception.
Pause or escalate when: a destination, data reuse, authoritative record, identity, or responsible owner is unknown; a broad marketing use case stands in for the specific workflow. Owner to name: sponsor or delegated workflow owner with data management, quality, privacy, and security reviewers.
Gate 2: test identity, access, and role separation
Evidence to request: an actor-to-system access matrix for sponsor, site, vendor support, and subprocessors; role grants, privileged access, provisioning and revocation, periodic access review, test/production separation, and a controlled sample showing who accessed which record or configuration. Ask whether support can see participant data, whether break-glass access exists, and who reviews unusual access.
Pause or escalate when: a shared or privileged identity cannot be attributed, support access has no owner or purpose, or a departing user cannot be revoked and verified. Owner to name: site and sponsor identity owners with vendor security and quality reviewers.
Gate 3: reconstruct audit trails and record corrections
Evidence to request: a controlled trace from source data and software version to output, human review, amendment, transfer, and downstream record. Request an audit-trail sample with actor, time, action, prior/current state where relevant, and retrievable metadata; then test an erroneous or disputed output and show correction plus downstream reconciliation. A screenshot of a log is an entry point, not proof that the full record can be reconstructed.
Pause or escalate when: the team cannot identify the original versus derived or final record, reproduce an affected output, preserve an attributable correction, or reconcile a changed record across systems. Owner to name: data management and quality with system custodians and investigator or site reviewers.
Gate 4: inspect suppliers and controlled changes
Evidence to request: an inventory of hosted systems, interfaces, model/API providers, subprocessors, data locations, and responsibilities; dated security-assessment evidence for the deployed configuration; change notices, version history, regression evidence, and a record of who can approve or roll back a material change. Ask whether protocol, data source, access role, interface, model, prompt, or supplier changes require renewed review before prior evidence is reused.
Pause or escalate when: a new destination or dependency appears without review, the vendor cannot identify the version behind a historical output, or evidence from a different configuration is treated as current. Owner to name: sponsor system owner and quality lead with vendor change and security owners.
Gate 5: isolate incidents and rehearse recovery
Evidence to request: detection and escalation paths; the actor who can pause new processing; an affected-record inventory method; evidence-preservation, notification, manual fallback, backup, restore, correction, downstream reconciliation, and restart steps. Request a dated exercise or controlled test relevant to the intended environment, with limitations and unresolved issues. Do not substitute a promise to respond for a tested way to find affected records.
Pause or escalate when: processing cannot be isolated, records or versions affected by an event cannot be identified, recovery has no tested owner, or downstream corrections cannot be verified. Owner to name: incident commander or security owner with sponsor quality, data management, and site operations.
Gate 6: decide, limit, and expire the review
Evidence to request: a control matrix linking each gate to applicability rationale, source/version/date, exact configuration, evidence pointer, owner, result, open issue, corrective action, approved boundary if any, expiry, and recheck trigger. Keep pass, fail, conditional, or open distinct; only a qualified local decision process can approve use. Reopen affected gates after a material system, protocol, actor, data, or record change.
Pause or escalate when: blank becomes pass, a material issue is netted against efficiency, the decision has no scope or expiry, or an old signoff is carried into a changed workflow. Owner to name: sponsor or delegated governance owner with qualified quality, security, privacy, clinical, and regulatory reviewers as applicable.
Build the six-part evidence packet
Request these six buyer-owned artifacts before a local decision. They are blank templates for evidence collection, not documents held or verified by HealthAIdir. Every material field begins open — owner/evidence required; unknown is not 0, and no incident report is not zero incidents. Set no default retention period, acceptable event rate, pass threshold, or product score here.
A. Workflow, data, and record map
Capture protocol and site scope, intended user and action, system boundary, source system, input/output class, authoritative copy, human review, downstream record, recipient, retention or archive, and evidence pointer. Record exclusions and unresolved classification beside each data path.
B. Actor, access, and subprocessor matrix
For each actor, capture organization and role, system and data accessible, purpose, grant/revocation owner, review date, privileged/support path, subprocessor or onward transfer, location, and evidence pointer. Leave the field open when access has not been verified.
C. Trace and transfer-reconciliation request
Specify one controlled sample or test ID, source record version, software configuration, output, reviewer action, audit-trail and metadata export, correction, downstream receipt, reconciliation result, evidence pointer, and limitation. Do not include real participant data in a public example.
D. Version, change, and applicability record
Capture protocol, system, interface, model, prompt if used, data source and supplier versions; change notice and effective date; impacted gates; regression or rollback evidence; owner; and the applicability rationale for each source. Mark each change as documentation-only, review-required, or approval-resetting through the local process rather than assuming a universal category.
E. Incident, backup, and recovery exercise request
Capture scenario, affected-record enumeration method, detection and pause authority, evidence-preservation owner, fallback, backup and restore evidence, correction and downstream reconciliation, restart decision, evidence pointer, open issue, and recheck trigger. An untested step remains open.
F. Evidence-to-decision control matrix
For each gate, retain the evidence pointer, owner, applicability rationale, test/configuration/date, pass, fail, conditional, or open state, open issue, remediation owner, approved boundary if locally granted, expiry, and recheck trigger. The matrix cannot replace the sponsor's or site's actual review. A failed privacy, security, integrity, safety, audit, or recovery gate remains visible beside any claimed operational benefit.
Apply official sources only to the identified scope
Use these materials to frame questions; none grants a product approval. The NIST Cybersecurity Framework 2.0, February 2024 groups security outcomes across governance, identification, protection, detection, response, and recovery. The NIST AI Risk Management Framework 1.0, January 2023 adds context-of-use, measurement, management, and AI governance vocabulary. Both are voluntary frameworks, not certifications, and AI RMF 1.0 was marked for revision when this guide's source map was checked on October 16, 2026. Recheck its version before publication.
For a clinical investigation to which they apply, the FDA E6(R3) Good Clinical Practice final guidance, September 2025 and FDA electronic systems, electronic records, and electronic signatures final Q&A, October 2024 support questions about responsible parties, fit-for-purpose computerized systems, access, data integrity, audit trails, transfer, retention, backup, and recovery. They do not establish that this AI system, record, or deployment is compliant. Determine the actual investigation and record role first. Under FDA Part 11 scope and application guidance, assess a predicate-rule record or FDA-submitted record before discussing Part 11; do not label every AI intermediate output a Part 11 record.
HIPAA is a conditional branch. If the actor is a covered entity or business associate handling ePHI, the HHS OCR Security Rule summary helps frame risk analysis, access, audit, and contingency questions. If a covered entity uses or discloses PHI for research, HHS OCR HIPAA and Research helps identify which specific pathway needs review. A sponsor, site, vendor, or trial dataset is not automatically covered; a BAA is not evidence that the data flow is authorized or secure. Recheck the current rule and obtain qualified applicability review.
Add the NIST Generative AI Profile, July 2024 only when the exact function uses generative AI: then ask about prompts, third-party models/APIs, sensitive-data reuse, output provenance, and prompt-injection or exfiltration tests. Apply the FDA and EMA good AI practice principles for drug development, January 2026 only when the workflow is part of drug or biologic development. The FDA January 2025 AI regulatory-decision guidance is draft, not for implementation; use its context-of-use vocabulary only if AI information is intended to support a specified FDA drug or biologic decision, after checking its current status.
Consider the NIH Data Management and Sharing Policy only for NIH-funded or NIH-conducted research generating scientific data. Consider ClinicalTrials.gov Protocol Registration and Results System only if the AI workflow touches registry drafting or submission; then identify the responsible submitter and field-level review. Neither source is a general security accreditation for trial AI. Omit these branches from a use case that does not involve them.
Hand off adjacent decisions
Keep a security-specific evidence packet while passing other decisions to their owners:
- Use the clinical trials AI buyer checklist for overall procurement completeness, participant protections, and evidence fit; return the status of the security and record-integrity gates to that broader decision.
- Use clinical trials AI compliance questions for jurisdiction, consent, privacy, and qualified applicability decisions. This page only flags the relevant record or data branch.
- Use clinical trials AI vendor evaluation for vendor comparison and contracts. This review does not rank suppliers or declare any one secure.
- Use clinical trials AI pilot planning for protocol-bound pilot design, measures, exceptions, and expansion decisions; supply the control evidence and hard stops as inputs.
- Use clinical trials AI workflow implementation for daily operating roles, handoffs, monitoring, and downtime procedures; this page requests the underlying security and recovery evidence.
- Use the clinical validation framework for model performance and intended-use evidence, and what to check before using AI with PHI for broader PHI-use questions. A security matrix answers neither in full.
If the buyer cannot map an exact workflow, link each gate to relevant evidence, or separate this packet from the broader buyer checklist, return to consolidation review. Do not infer a redirect, canonical, noindex, removal, or other public URL action from that editorial return; those require separate, fresh evidence and approval.
Evidence boundary
This guide draws on public FDA, HHS, NIH, NIST, and ClinicalTrials.gov materials for their stated scope. It reports no product test, sponsor or site interview, protocol review, vendor configuration, security assessment, incident, restore exercise, participant result, approval, or legal conclusion. A certificate, BAA, policy, and vendor slide may be useful inputs but do not prove the controls operated in a local study. Leave unresolved fields open — owner/evidence required and recheck sources, system versions, and applicability before any operational decision.